1. Which of the following respiratory disorders is projected to increase in rank as a leading cause of death?
A. asthma
B. chronic obstructive pulmonary disease
C. pulmonary hypertension
D. chronic bronchitis
2. Peak expiratory flow monitoring for patients with asthma is LEAST appropriate for those who:
A. are elderly
B. are obese
C. have difficulty identifying asthma symptoms
D. have mild intermittent asthma
3. For a 6-year old patient with asthma receiving salmeterol and fluticasone propionate (Advair Diskus) who needs to augment therapy from step 3 to 4, what is an appropriate increased dosage of fluticasone?
A. 50 mcg
B. 100 mcg
C. 250 mcg
D. 500 mcg
4. Appropriate patient counseling on inhaler, spacer, and VHC use includes all of the following EXCEPT:
A. coordination of breathing is important with use of MDIs
B. a minimum force of inhalation is required to aerosolize drugs administered via DPI
C. VHCs allow for multiple inhalations when connected to an inhaler
D. spacers and VHCs should be cleaned with water only and towel-dried
5. Which of the following is TRUE regarding the newly approved inhaled respiratory agents, vilanterol/umeclidinium (Anoro Ellipta) and vilanterol/fluticasone furoate (Breo Ellipta)?
A. both are approved for treatment of asthma and COPD
B. both are indicated for once-daily administration
C. both are combinations of a LABA and an ICS
D. both are combinations of a LABA and a LAMA
6. Which of the following regimens is preferred initial treatment in a patient initiating pharmacotherapy for COPD with few symptoms and low exacerbation risk?
A. ipratropium 4 times daily and albuterol as needed
B. aclidinium twice daily and albuterol as needed
C. indacaterol once daily and albuterol as needed
D. budesonide twice daily and albuterol as needed
7. Which of the following is FALSE regarding antibiotic use in patients with COPD?
A. Antibiotics may be used in patients with increased sputum purulence and increased dyspnea
B. Antibiotics commonly used in COPD exacerbation include macrolides, cephalosporins, and doxycycline
C. macrolides and doxycycline may be used chronically to prevent exacerbation
D. Duration of antibiotic therapy for COPD exacerbation is typically 7 to 10 days
8. What is an appropriate goal INR range for a patent with pulmonary hypertension who has no other compelling issues for anticoagulation?
A. 1.0 to 2.0
B. 1.5 to 2.5
C. 2.0 to 3.0
D. 2.5 to 3.5
9. Which of the following is FALSE regarding treprostinil?
A. it is available as a solution rather than powder for reconstitution
B. it has a shorter half-life than epoprostenol
C. it is available as an inhaled formulation
D. an appropriate initial dosage is 1.25 ng/kg/min
10. Which of the following is TRUE regarding monitoring of patients receiving ERAs?
A. liver function testing should be performed monthly for patients receiving any ERA
B. pregnancy must be excluded prior to initiation of macitentan only
C. complete blood counts should be taken every 3 months for patients receiving bosentan
D. only patients receiving ambrisentan should avoid CYP 3A4 inhibitors and inducers
Evaluation Questions
11. To what extent did the program meet objective #1?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
12. To what extent did the program meet objective #2?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
13. To what extent did the program meet objective #3?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
14. To what extent did the program meet objective #4?
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
15. Rate the effectiveness of how well the program related to your educational needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
16. Rate how well the active learning strategies (questions, cases, discussions) were appropriate and effective learning tools:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
17. Rate the quality of the faculty:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
18. Rate the effectiveness and the overall usefulness of the material presented:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
19. Rate the appropriateness of the examination for this activity:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
20. Rate the effectiveness of how well the activity related to your practice needs:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
21. Rate the effectiveness of how well the activity will help you improve patient care:
A. Excellent
B. Very Good
C. Good
D. Fair
E. Poor
22. Will the information presented cause you to change your practice?
A. Yes
B. No
23. Are you committed to making these changes?
A. Yes
B. No
24. As a result of this activity, did you learn something new?
A. Yes
B. No
25. What is your practice setting or area of practice?
A. Community Pharmacy/Independent
B. Community Pharmacy/Chain
C. Hospital/Health Systems
D. Administrative/Pharmacy Director
E. Critical Care Pharmacy
F. Long-term Care
G. Managed Care/PBM
H. Oncology/Specialty Pharmacy
I. Industry/Manufacturing
26. How many years have you been in practice?
A. <5
B. 5 – 10
C. 11 – 20
D. >20